PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7717710

[Phase I study].

T Taguchi
View original source ↗Export metadata ↓

Abstract

Criticisms and proposals were presented from the standpoint of implementation with regard to the objectives, person in charge, test facilities, patients tested and test design in the first phase cited in the "Guidelines For Methods To Evaluate Drugs for Malignant Tumors at the Clinical Level." Moreover, it was proposed that the public be informed as to the need and importance of scientific, theoretical and highly cost-efficient clinical trials.

Explore related subjects

Clinical Trials, Phase I as TopicCohort StudiesCost-Benefit AnalysisHumansMulticenter Studies as TopicNeoplasmsPatient SelectionPractice Guidelines as TopicResearch DesignEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Taguchi. 1995. [Phase I study].. https://pubmed.ncbi.nlm.nih.gov/7717710/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1997

Hemodynamic surrogate end-points in phase I studies?

Clinical pharmacology studies in healthy volunteers ("human pharmacology studies") characterize the pharmacokinetic and pharmacodynamic hallmarks of pharmacological action and their interrelation in the intact effector system unconfounded by disease and comedication. They constitute a valuable basis for the subsequent explicit investigation of the clinical efficacy, safety, efficiency, and therapeutic benefit in patients, but are not a valid surrogate for them.

Clinical Trials, Phase I as Topic↗
PubMed1997

New phase I trial methodology.

Phase I trial design is constantly evolving to adapt to deficiencies in traditional methods and to accommodate newer rationally designed agents. This article discusses some of the important aspects of the design of phase I studies with particular reference to identifying new methods of safer but rapid dose escalation and reproducible end points such as maximum tolerated dose and recommended phase II dose. Given the explosion of rationally designed drugs capable of pathway specific inhibition, we also discuss potential strategies in designing trials with these agents. It is hoped that future strategies incorporate the existing methodologies with newer dose titration examples to complete phase I trials in a rapid and timely fashion.

Clinical Trials, Phase I as Topic↗